Details of the Drug

General Information of Drug (ID: DMDBX5F)

Drug Name

Ivermectin

Synonyms

I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN)

Indication

Disease Entry	ICD 11	Status	REF
Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[1], [2]

Therapeutic Class

Antiprotozoal Agents

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

875.1

Topological Polar Surface Area (xlogp)

4.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.17141 micromolar/kg/day [4]
Water Solubility: The ability of drug to dissolve in water is measured as 4 mg/mL [3]

Chemical Identifiers

Formula: C48H74O14
IUPAC Name: (1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
Canonical SMILES: CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\\C)C
InChI: InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
InChIKey: AZSNMRSAGSSBNP-XPNPUAGNSA-N

Cross-matching ID

PubChem CID: 6321424
ChEBI ID: CHEBI:63941
CAS Number: 71827-03-7
DrugBank ID: DB00602
TTD ID: D09YHJ
VARIDT ID: DR00147
INTEDE ID: DR0899
ACDINA ID: D00340

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Onchocerca Glutamate-gated chloride channel (Onchoc GluCl)	TTSNVHO	Q25634_ONCVO	Activator	[5]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[6]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ivermectin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Ivermectin due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[35]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Ivermectin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[36]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Ivermectin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[35]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Ivermectin caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Ivermectin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Ivermectin caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Ivermectin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Ivermectin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Ivermectin caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[39]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Ivermectin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[40]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Ivermectin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[41]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Ivermectin caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[42]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Ivermectin caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Ivermectin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Ivermectin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Ivermectin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Ivermectin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Ivermectin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[45]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Ivermectin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[46]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Ivermectin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[47]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Ivermectin caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Ivermectin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Ivermectin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Ivermectin caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Ivermectin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Ivermectin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Ivermectin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Ivermectin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Ivermectin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Ivermectin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[51]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Ivermectin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[52]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Ivermectin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[53]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Ivermectin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Ivermectin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[54]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Ivermectin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[55]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Ivermectin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[56]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Ivermectin due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[57]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Ivermectin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[58]
Modafinil	DMYILBE	Minor	Increased metabolism of Ivermectin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[59]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Ivermectin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[60]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ivermectin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[61]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Ivermectin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[62]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Ivermectin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[63]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Ivermectin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[64]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Ivermectin and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[65]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Ivermectin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[35]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Ivermectin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[39]
Armodafinil	DMGB035	Minor	Increased metabolism of Ivermectin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[59]
LEE011	DMMX75K	Moderate	Decreased metabolism of Ivermectin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[66]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Ivermectin caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[35]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Ivermectin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[67]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Ivermectin and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[65]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Ivermectin and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[65]
-----------


⏷ Show the Full List of 53 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ivermectin 3 mg tablet	3 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2373).
2	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
3	BDDCS applied to over 900 drugs
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008 Nov;90(4):589-95.
6	Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79.
7	MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91.
8	Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998 Mar;28(3):313-21.
9	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
19	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
20	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
21	Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
22	Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
23	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
24	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
25	Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
26	Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
27	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
28	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
29	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
30	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
31	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
32	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
33	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
34	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
35	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
37	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
38	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
39	Cerner Multum, Inc. "Australian Product Information.".
40	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
41	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
42	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
43	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
44	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
45	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
46	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
47	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
48	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
49	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
50	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
51	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
52	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
53	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
54	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
55	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
56	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
57	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
58	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
59	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
60	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
61	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
62	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
63	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
64	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
65	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
66	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
67	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.